Meera Mahalingam, MBBS, PhD, FRCPath

Title: Professor of Dermatology, Pathology and Laboratory Medicine, BUSM
Program Director, Dermatopathology Fellowship training

Dermatopathology Fellowship: Dermatopathology Section, Department of Dermatology, BUSM

Board Certifications: Anatomic and Clinical Pathology, Dermatopathology

Background: Meera Mahalingam received her medical degree in India (MBBS) and trained in pathology initially in the UK and subsequently in the USA. She is a board certified pathologist (UK and USA) and a board certified dermatopathologist (USA). She joined BUSM in 2007 prior to which she was Director of Dermatopathology, UMASS Medical School. She has served on the Board of the American Society of Dermatopathology since 2003 as Director of Quality Assurance and Laboratory Proficiency (2003-07), serves on the editorial board of the Journal of Cutaneous Pathology (2007-) and has several publications in reputed scientific journals such as Cell (2008, 2010), Modern Pathology (2008-2010), British Journal of Dermatology (2009, 2010), Human Pathology (2009, 2010), Histopathology (2010) and dermatopathopathology journals.

Special interests: Cutaneous lymphoproliferative disease, pigmented lesions

Research Interests: "My primary research interest focuses on improving diagnostic accuracy of various skin tumors with particular emphasis on atypical pigmented lesions. To this end, I utilize techniques such as the genomic analyses of select mutations affecting the MAP kinase pathway (known to be commonly affected in melanocytic neoplasias) and immunohistochemistry to explore their potential as ancillary methods for diagnosis or prognosis."

Select Publications:

1. Mahalingam M, Nguyen LP, Richards JE, Muzikansky A, Hoang MP. The Diagnostic Utility of Immunohistochemistry in Distinguishing Primary Skin Adnexal Carcinomas from Metastatic Adenocarcinoma to Skin: an Immunohistochemical Reappraisal Using Cytokeratin 15, Nestin, p63, D2-40, and Calretinin. Mod Pathol, 2010; 23(5): 713

2. DeCarlo K, Yang S, Emley A, Wajapeyee N, Green M, Mahalingam M. Oncogenic BRAF positive dysplastic nevi and the tumor suppressor IGFBP7– challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol, 2010; 41(6):886

3. Hoang MP, Keady M, Mahalingam M. Stem cell markers (cytokeratin 15, CD34 and nestin) in primary scarring and non-scarring alopecia. Br J Dermatol 2009; 160:609

4. Dadzie O, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma – clues to melanomagenesis. Br J Dermatol 2009; 160:368

5. Wajapayee N, Serra R, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence through an autocrine/paracrine pathway mediated by the secreted protein IGFBP7. Cell 2008; 132:363

Additional Information: Link to CV in detail